Facebook Pixel Code
About Sickkids
About SickKids

Jane McGlade, PhD

Research Institute
Associate Chief of Research, Faculty Development
Research Institute

Director
SIDNET

Principal Investigator
The Arthur and Sonia Labatt Brain Tumour Research Centre

Senior Scientist
Cell Biology

University of Toronto
Professor
Medical Biophysics


Fax: 416-813-8456
Email: jmcglade@sickkids.ca

For more information, visit:

McGlade Lab

Research Interests

  • Signal transduction
  • Cancer
  • Protein biochemistry
  • Development

Research activities

My research is directed towards understanding the regulation of signal transduction pathways, that control normal embryonic development and cellular function, and which are relevant to disease states such as cancer. Recently we have focused specifically on a family of intracellular adapter molecules that function to integrate, localize, and down regulate signal transduction cascades. My lab has identified new adapters such as GADS and MARS that function in antigen receptor signalling, and NUMB and LNX which regulate the activity of transmembrane receptors that determine cell fate during development.

Future research interests

Currently work in my laboratory focuses on the functional characterization of these molecules, as well as the on going discovery of new regulators of signal transduction pathways. In addition the lab studies the role of adaptors in directing protein ubiquitylation and vesicle trafficking.

External Funding

Role of the SLAP adaptor proteins in ubiquitin dependent regulation of receptor tyrosine kinases.
2008-2013, Canadian Institutes of Health Research

The E3 ligase LNX2 in Wnt signaling, cell polarity and cancer.
2009-2014, Canadian Cancer Society Research Institute

Role of the CRB1-EPB41L5 complex in retinal degeneration.
2010-2013, Foundation Fighting Blindness-Canada

Function and regulation of Numb isoform expression in cancer.
2010-2015, Canadian Institutes of Health Research

Publications

Publications on Pub Med

Intellectual Property

Adapter Gene, Corporate Ventures